The glial marker YKL-40 is decreased in synucleinopathies

Movement Disorders

Volumn 28, Issue 13, 2013, Pages 1882-1885

  Olsson, Bob ^a   Constantinescu, Radu ^a   Holmberg, Björn ^a   Andreasen, Niels ^b   Blennow, Kaj ^a   Zetterberg, Henrik ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Astrocytes; Biomarker; Cerebrospinal fluid; Microglia; Parkinson's disease; Parkinsonian disorders

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; PROTEIN YKL 40; SOLUBLE CD14 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTE; BLOOD ANALYSIS; CELL ACTIVATION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; FEMALE; HUMAN; MALE; MICROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; TAUOPATHY;

ASTROCYTES; BIOMARKER; CEREBROSPINAL FLUID; MICROGLIA; PARKINSON'S DISEASE; PARKINSONIAN DISORDERS;

ADIPOKINES; AGED; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANTIGENS, CD14; BASAL GANGLIA DISEASES; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE; TAUOPATHIES;

EID: 84887593053     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25589     Document Type: Article

References (28)

1. Lewy FH. Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilk 1913;50:50-55.
2. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
3. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
4. Norenberg W, Illes P, Gebicke-Haerter PJ. Sodium channel in isolated human brain macrophages (microglia). Glia 1994;10:165-172.
5. Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 2009;87:2578-2590.
6. Bonneh-Barkay D, Bissel SJ, Wang G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008;173:130-143.
7. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 2010;3:226-237.
8. Galea E, Reis DJ, Fox ES, Xu H, Feinstein DL. CD14 mediates endotoxin induction of nitric oxide synthase in cultured brain glial cells. J Neuroimmunol 1996;64:19-28.
9. Rejman JJ, Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 1988;150:329-334.
10. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-25810.
11. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988;141:547-552.
12. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998;395:284-288.
13. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088.
14. Lee HK, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006;24:153-163.
15. Baumann CL, Aspalter IM, Sharif O, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010;207:2689-2701.
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
17. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
18. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
19. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
20. Olsson B, Hertze J, Lautner R, et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 2013;33:45-53.
21. Mackenzie IR. Activated microglia in dementia with Lewy bodies. Neurology 2000;55:132-134.
22. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221-227.
23. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000;95:425-432.
24. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993;52:1-6.
25. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-4368.
26. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases [serial online]. J Neuroinflammation 2010;7:34.
27. Schwarz SC, Seufferlein T, Liptay S, et al. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport 1998;9:3029-3032.
28. Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997;23:201-212.